Search results
Showing 201 to 250 of 1882 results for carers
Linzagolix for treating moderate to severe symptoms of uterine fibroids [ID6190]
In development [GID-TA11131] Expected publication date: TBC
Selpercatinib for untreated advanced thyroid cancer with RET alterations [ID6132]
In development [GID-TA11047] Expected publication date: 26 June 2024
This quality standard covers preventing, assessing and managing pressure ulcers (bed sores) in adults, young people and children. It includes risk assessment and support to prevent pressure ulcers. It applies to all settings, including hospitals, care homes (with and without nursing care) and people’s own homes.
View quality statements for QS89Show all sections
Sections for QS89
- Introduction
- List of quality statements
- Quality statement 1: Pressure ulcer risk assessment in hospitals and care homes with nursing
- Quality statement 2: Pressure ulcer risk assessment by community nursing services
- Quality statement 3: Pressure ulcer risk reassessment
- Quality statement 4: Skin assessment
- Quality statement 5: Advice on repositioning
- Quality statement 6: Help with repositioning
Hybrid closed loop systems for managing blood glucose levels in type 1 diabetes (TA943)
Evidence-based recommendations on hybrid closed loop systems for managing blood glucose levels in type 1 diabetes.
This guideline covers the nutrition of pregnant women, including women who are planning to become pregnant, mothers and other carers of children aged under 5 and their children. In particular, it aims to address disparities in the nutrition of low-income and other disadvantaged groups compared with the general population.
Arranging services for people with a learning disability and behaviour that challenges
service development training, information and support for families and carers to enable them to meet the needs of the person, access...
Asfotase alfa for treating paediatric-onset hypophosphatasia (HST23)
Evidence-based recommendations on asfotase alfa (Strensiq) for treating paediatric-onset hypophosphatasia in babies, children, young people and adults.
Evidence-based recommendations on ataluren (Translarna) for Duchenne muscular dystrophy with a nonsense mutation in the dystrophin gene in people 2 years and over who can walk.
Everything you need to know about payments and expenses for lay members on a NICE committee
In development [GID-TA11316] Expected publication date: 23 October 2024
Fosdenopterin for treating molybdenum cofactor deficiency type A [ID6264]
In development [GID-HST10055] Expected publication date: 11 September 2024
Relugolix for treating hormone-sensitive prostate cancer [ID6187]
In development [GID-TA11141] Expected publication date: TBC
Elafibranor for treating primary biliary cholangitis [ID6331]
In development [GID-TA11378] Expected publication date: TBC
In development [GID-TA11370] Expected publication date: 16 October 2024
In development [GID-TA11371] Expected publication date: 11 September 2024
Social, emotional and mental wellbeing in primary and secondary education (NG223)
This guideline covers ways to support social, emotional and mental wellbeing in children and young people in primary and secondary education (key stages 1 to 5), and people 25 years and under with special educational needs or disability in further education colleges. It aims to promote good social, emotional and psychological health to protect children and young people against behavioural and health problems.
Antimicrobial stewardship: systems and processes for effective antimicrobial medicine use (NG15)
This guideline covers the effective use of antimicrobials (including antibiotics) in children, young people and adults. It aims to change prescribing practice to help slow the emergence of antimicrobial resistance and ensure that antimicrobials remain an effective treatment for infection.
This quality standard covers assessment and treatment of drug use disorders in adults (aged 18 and over). It includes treating the misuse of opioids, cannabis, stimulants and other drugs in all settings, including inpatient and specialist residential and community-based treatment settings, and prison services. It describes high-quality care in priority areas for improvement.
View quality statements for QS23Show all sections
Sections for QS23
- Introduction and overview
- List of quality statements
- Quality statement 1: Needle and syringe programmes
- Quality statement 2: Assessment
- Quality statement 3: Families and carers
- Quality statement 4: Blood-borne viruses
- Quality statement 5: Information and advice
- Quality statement 6: Keyworking – psychosocial interventions
In development [GID-TA11390] Expected publication date: 24 July 2024
Ritlecitinib for treating severe alopecia areata in people 12 years and over (TA958)
Evidence-based recommendations on ritlecitinib (Litfulo) for treating severe alopecia areata in people 12 years and over.
This guideline covers good practice for developing, authorising, using and updating patient group directions. It also offers advice on deciding whether a patient group direction is needed.
View recommendations for MPG2Show all sections
Common mental health problems: identification and pathways to care (CG123)
This guideline covers care for people aged 18 and over with common mental health problems, with a focus on primary care. It aims to improve access to services for adults and how mental health problems are identified and assessed, and makes recommendations on local care pathways.
In development [GID-TA11288] Expected publication date: 19 June 2024
Exagamglogene autotemcel for treating sickle cell disease [ID4016]
In development [GID-TA11249] Expected publication date: 17 July 2024
This guideline covers the planning, delivery and review of social work interventions for adults who have complex needs. It promotes ways for social work professionals, other care staff and people with complex needs to work together to make decisions about care and support.
In development [GID-TA11184] Expected publication date: TBC
In development [GID-TA11167] Expected publication date: TBC
Efanesoctocog alfa for treating and preventing bleeding episodes in haemophilia A [ID6170]
In development [GID-TA11106] Expected publication date: TBC
Avapritinib for treating advanced systemic mastocytosis ID3770
In development [GID-TA11382] Expected publication date: TBC
In development [GID-TA11381] Expected publication date: 15 May 2024
This guideline covers managing hip fracture in adults. It aims to improve care from the time people aged 18 and over are admitted to hospital through to when they return to the community. Recommendations emphasise the importance of early surgery and coordinating care through a multidisciplinary Hip Fracture Programme to help people recover faster and regain their mobility.
This guideline covers complex rehabilitation needs after traumatic injury, including assessment and goal setting, rehabilitation plans and programmes, physical, psychological and cognitive rehabilitation, rehabilitation for specific injuries, coordination of rehabilitation in hospital, at discharge and in the community, and commissioning and organising rehabilitation services.
Crovalimab for treating paroxysmal nocturnal haemoglobinuria [ID6140]
In development [GID-TA11062] Expected publication date: 16 October 2024
This guideline covers diagnosing and managing cystic fibrosis. It specifies how to monitor the condition and manage the symptoms to improve quality of life. There are also detailed recommendations on treating the most common infections in people with cystic fibrosis.
In development [GID-TA10143] Expected publication date: TBC
Burosumab for treating X-linked hypophosphataemia in adults [ID3822]
In development [GID-TA10733] Expected publication date: TBC
Somapacitan for treating growth hormone deficiency in children [ID6178]
In development [GID-TA11153] Expected publication date: TBC
End of life care for infants, children and young people (QS160)
This quality standard covers end of life care for infants, children and young people (from birth to 18 years) who have a life-limiting condition. Life-limiting conditions are those that are expected to result in an early death for the person. It also covers support for family members and carers. It describes high-quality care in priority areas for improvement.
View quality statements for QS160Show all sections
Sections for QS160
- Quality statements
- Quality statement 1: Advance care plan
- Quality statement 2: Named medical specialist
- Quality statement 3: Emotional and psychological support
- Quality statement 4: Specialist paediatric palliative care team
- Quality statement 5: Support for grief and loss for parents or carers
- Quality statement 6: Care at home
- About this quality standard
Supporting the health and care system to implement virtual wards
they want. Based on this, give the patient (and their family members and/or carers if appropriate) clear, consistent, evidence-based,...
In development [GID-TA10999] Expected publication date: 21 August 2024
Diarrhoea and vomiting caused by gastroenteritis in under 5s: diagnosis and management (CG84)
This guideline covers diagnosing, managing and referring infants and young children younger than 5 years who present with acute diarrhoea (lasting up to 14 days) with or without vomiting. It aims to improve the diagnosis and management of infective gastroenteritis and appropriate escalation of care.
This guideline covers general principles for prescribing and managing withdrawal from opioids, benzodiazepines, gabapentinoids, Z-drugs and antidepressants in primary and secondary care.
Evidence-based recommendations on adalimumab (Humira), etanercept (Enbrel) and ustekinumab (Stelara) for plaque psoriasis in children and young people.
Rozanolixizumab for treating antibody-positive generalised myasthenia gravis [ID5092]
In development [GID-TA10994] Expected publication date: TBC
This guideline covers diagnosing and treating jaundice, which is caused by increased levels of bilirubin in the blood, in newborn babies (neonates). It aims to help detect or prevent very high levels of bilirubin, which can be harmful if not treated.
This guideline covers identifying and managing otitis media with effusion (OME), also known as ‘glue ear’, in children younger than 12 years. It aims to improve hearing and quality of life in children with OME.
This quality standard covers assessing and managing bedwetting (nocturnal enuresis) in children and young people (aged 18 and under). It describes high-quality care in priority areas for improvement.
View quality statements for QS70Show all sections
This quality standard covers diagnosing and managing stroke in adults (over 16). It includes diagnosis, initial management, acute-phase care, rehabilitation and long-term support for people with stroke. It describes high-quality care in priority areas for improvement.
View quality statements for QS2Show all sections
Sections for QS2
- Quality statements
- Quality statement 1: Prompt admission to specialist acute stroke units
- Quality statement 2: Intensity of stroke rehabilitation
- Quality statement 3: Access to a clinical psychologist
- Quality statement 4: Early supported discharge
- Quality statement 5: Return to work
- Quality statement 6: Regular review of rehabilitation goals
- Quality statement 7: Regular review of health and social care needs
This quality standard covers diagnosing and managing epilepsies in children, young people and adults. It describes high-quality care in priority areas for improvement.
View quality statements for QS211Show all sections
Sections for QS211
- Quality statements
- Quality statement 1: Referral and assessment after first seizure
- Quality statement 2: Referral to tertiary specialist services
- Quality statement 3: Epilepsy specialist nurse
- Quality statement 4: Epilepsy care plan
- Quality statement 5: Mental health and wellbeing
- Quality statement 6: Neurodevelopment and learning disabilities
- Update information
In development [GID-TA11156] Expected publication date: 19 June 2024